Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients

Jinsil Seong, Hee Chul Park, KwangHyub Han, Chae Yoon Chon, Sung Sil Chu, Gwi Eon Kim, Chang-Ok Suh

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Purpose: Recent reports have shown that a portion of the liver can tolerate higher radiation doses, which can be further accomplished by the application of 3-dimensional conformal radiotherapy (3-DCRT). The purpose of this study was to investigate the efficacy and toxicity of 3-DCRT combined with transcatheter arterial chemoembolization (TACE) for HCC in the cirrhotic patients. Methods and materials: From 1994 to 2000, 50 HCC patients with liver cirrhosis (LC) were included in this study. The degree of LC was Child A in 38 and Child B in 12. The UICC stages were II in 12, III in 16, and IVa in 22. The mean tumor size was 8.3±3.5 cm. Patients were treated with TACE and then followed by 3-DCRT within 7-14 days. 3-DCRT planning was used to define both the target and normal liver volumes. The total dose of radiation (mean 50.1±8.3 Gy) was determined by the fractional volume of normal liver receiving 50% of the isocenter dose. Results: A partial response (PR) was observed in 33 patients (66% . A subsequent surgical resection was successful in three patients, showing complete necrosis in one and near total necrosis in two. Most common acute toxicity was alteration in liver function test (13 patients and none of the patients showed an acute toxicity more than grade 3. Subacute and chronic toxicity involved radiation induced liver disease (RILD) (six patients) and gastrointestinal toxicity (seven patients; ulcer in five and hemorrhagic mucositis in two). The actuarial survival rate at 3 years was 43% from the commencement of radiotherapy. Conclusions: Radiotherapy using 3-DCRT combined with TACE can achieve a substantial tumor response and survival rate for HCC in the cirrhotic patients.

Original languageEnglish
Pages (from-to)30-35
Number of pages6
JournalHepatology Research
Volume27
Issue number1
DOIs
Publication statusPublished - 2003 Sep 1

Fingerprint

Conformal Radiotherapy
Hepatocellular Carcinoma
Radiation
Liver Cirrhosis
Liver
Necrosis
Radiotherapy
Survival Rate
Mucositis
Liver Function Tests
Ulcer
Liver Diseases
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cite this

@article{50cf6c77af564e5cbebdabbddcae4b11,
title = "Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients",
abstract = "Purpose: Recent reports have shown that a portion of the liver can tolerate higher radiation doses, which can be further accomplished by the application of 3-dimensional conformal radiotherapy (3-DCRT). The purpose of this study was to investigate the efficacy and toxicity of 3-DCRT combined with transcatheter arterial chemoembolization (TACE) for HCC in the cirrhotic patients. Methods and materials: From 1994 to 2000, 50 HCC patients with liver cirrhosis (LC) were included in this study. The degree of LC was Child A in 38 and Child B in 12. The UICC stages were II in 12, III in 16, and IVa in 22. The mean tumor size was 8.3±3.5 cm. Patients were treated with TACE and then followed by 3-DCRT within 7-14 days. 3-DCRT planning was used to define both the target and normal liver volumes. The total dose of radiation (mean 50.1±8.3 Gy) was determined by the fractional volume of normal liver receiving 50{\%} of the isocenter dose. Results: A partial response (PR) was observed in 33 patients (66{\%} . A subsequent surgical resection was successful in three patients, showing complete necrosis in one and near total necrosis in two. Most common acute toxicity was alteration in liver function test (13 patients and none of the patients showed an acute toxicity more than grade 3. Subacute and chronic toxicity involved radiation induced liver disease (RILD) (six patients) and gastrointestinal toxicity (seven patients; ulcer in five and hemorrhagic mucositis in two). The actuarial survival rate at 3 years was 43{\%} from the commencement of radiotherapy. Conclusions: Radiotherapy using 3-DCRT combined with TACE can achieve a substantial tumor response and survival rate for HCC in the cirrhotic patients.",
author = "Jinsil Seong and Park, {Hee Chul} and KwangHyub Han and Chon, {Chae Yoon} and Chu, {Sung Sil} and Kim, {Gwi Eon} and Chang-Ok Suh",
year = "2003",
month = "9",
day = "1",
doi = "10.1016/S1386-6346(03)00162-1",
language = "English",
volume = "27",
pages = "30--35",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "1",

}

Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. / Seong, Jinsil; Park, Hee Chul; Han, KwangHyub; Chon, Chae Yoon; Chu, Sung Sil; Kim, Gwi Eon; Suh, Chang-Ok.

In: Hepatology Research, Vol. 27, No. 1, 01.09.2003, p. 30-35.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients

AU - Seong, Jinsil

AU - Park, Hee Chul

AU - Han, KwangHyub

AU - Chon, Chae Yoon

AU - Chu, Sung Sil

AU - Kim, Gwi Eon

AU - Suh, Chang-Ok

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Purpose: Recent reports have shown that a portion of the liver can tolerate higher radiation doses, which can be further accomplished by the application of 3-dimensional conformal radiotherapy (3-DCRT). The purpose of this study was to investigate the efficacy and toxicity of 3-DCRT combined with transcatheter arterial chemoembolization (TACE) for HCC in the cirrhotic patients. Methods and materials: From 1994 to 2000, 50 HCC patients with liver cirrhosis (LC) were included in this study. The degree of LC was Child A in 38 and Child B in 12. The UICC stages were II in 12, III in 16, and IVa in 22. The mean tumor size was 8.3±3.5 cm. Patients were treated with TACE and then followed by 3-DCRT within 7-14 days. 3-DCRT planning was used to define both the target and normal liver volumes. The total dose of radiation (mean 50.1±8.3 Gy) was determined by the fractional volume of normal liver receiving 50% of the isocenter dose. Results: A partial response (PR) was observed in 33 patients (66% . A subsequent surgical resection was successful in three patients, showing complete necrosis in one and near total necrosis in two. Most common acute toxicity was alteration in liver function test (13 patients and none of the patients showed an acute toxicity more than grade 3. Subacute and chronic toxicity involved radiation induced liver disease (RILD) (six patients) and gastrointestinal toxicity (seven patients; ulcer in five and hemorrhagic mucositis in two). The actuarial survival rate at 3 years was 43% from the commencement of radiotherapy. Conclusions: Radiotherapy using 3-DCRT combined with TACE can achieve a substantial tumor response and survival rate for HCC in the cirrhotic patients.

AB - Purpose: Recent reports have shown that a portion of the liver can tolerate higher radiation doses, which can be further accomplished by the application of 3-dimensional conformal radiotherapy (3-DCRT). The purpose of this study was to investigate the efficacy and toxicity of 3-DCRT combined with transcatheter arterial chemoembolization (TACE) for HCC in the cirrhotic patients. Methods and materials: From 1994 to 2000, 50 HCC patients with liver cirrhosis (LC) were included in this study. The degree of LC was Child A in 38 and Child B in 12. The UICC stages were II in 12, III in 16, and IVa in 22. The mean tumor size was 8.3±3.5 cm. Patients were treated with TACE and then followed by 3-DCRT within 7-14 days. 3-DCRT planning was used to define both the target and normal liver volumes. The total dose of radiation (mean 50.1±8.3 Gy) was determined by the fractional volume of normal liver receiving 50% of the isocenter dose. Results: A partial response (PR) was observed in 33 patients (66% . A subsequent surgical resection was successful in three patients, showing complete necrosis in one and near total necrosis in two. Most common acute toxicity was alteration in liver function test (13 patients and none of the patients showed an acute toxicity more than grade 3. Subacute and chronic toxicity involved radiation induced liver disease (RILD) (six patients) and gastrointestinal toxicity (seven patients; ulcer in five and hemorrhagic mucositis in two). The actuarial survival rate at 3 years was 43% from the commencement of radiotherapy. Conclusions: Radiotherapy using 3-DCRT combined with TACE can achieve a substantial tumor response and survival rate for HCC in the cirrhotic patients.

UR - http://www.scopus.com/inward/record.url?scp=0141828599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141828599&partnerID=8YFLogxK

U2 - 10.1016/S1386-6346(03)00162-1

DO - 10.1016/S1386-6346(03)00162-1

M3 - Article

VL - 27

SP - 30

EP - 35

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 1

ER -